MMP13-IN-2

立即咨询

MMP13-IN-2

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

935759-55-0

包装与价格：

包装	价格(元)
10mg	电议
25mg	电议

产品介绍

MMP13-IN-2 是一种有效、选择性和口服活性的 MMP-13 抑制剂。MMP13-IN-2 对 MMP-13 具有优异的效价 (IC50=0.036 nM)，对 MMP-1、3、7、8、9、14 和 TACE 的选择性(大于 1500 倍)。MMP13-IN-2 在体外具有阻止软骨释放胶原蛋白的能力。MMP13-IN-2 具有胶原酶相关疾病研究的潜力。

Cas No.	935759-55-0
分子式	C₂₄H₁₉FN₆O₄S
分子量	506.51
溶解度	DMSO : 100 mg/mL (197.43 mM; ultrasonic and warming and heat to 60°C)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	MMP13-IN-2 is a potent, selective and orally activeMMP-13inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC₅₀=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research^[1]. In a bovine nasal cartilage (BNC) assay, the chondrocyte-mediated degradation of cartilage was studied using bovine nasal cartilage slices cultured for up to 14 days. MMP13-IN-2 (0.01-1 µM) is effective at preventing the IL-1/OSM induced in vitro degradation of BNC (-17.6%, 48.4% and 70.8% inhibition of cartilage degradation, respectively).^[1]. MMP13-IN-2 (oral gavage; 1 mg/kg) shows the best combination of CYP3A4 inhibition risk and oral exposure at a dose of 1 mg/kg in rats and mice (F% = 33 and 38, respectively)^[1].